Vyant Bio Announces Participation at the 2022 CDKL5 Forum Hosted by the Loulou Foundation on November 7-8, 2022
Platform and Poster Presentations on Vyant Bio’s Human First Drug Discovery Platform and Progress on CDKL5 Deficiency Disorder (CDD)
Related news for (VYNT)
- Vyant Bio Announces Filing of Form 25 for Voluntary Nasdaq Delisting and SEC Deregistration
- Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation
- Vyant Bio Presents Key Takeaways from Platform and Poster Presentations at the 2022 CDKL5 Forum Hosted by the Loulou Foundation
